中国实用妇科与产科杂志2026，Vol.42Issue(5)：515-520,6.DOI:10.19538/j.fk2026050108
晚期及复发性子宫内膜癌规范化辅助治疗
Standardized adjuvant therapy for advanced and recurrent endometrial cancer
摘要
Abstract
Advanced and recurrent endometrial cancer is highly heterogeneous,and treatment decisions need to be stratified based on disease status,pathological type,molecular markers,and prior treatment exposure.In recent years,with molecular classification gradually entering clinical practice,the treatment for advanced and recurrent endometrial cancer has shifted from a predominantly empirical chemotherapy approach to individualized therapy based on biological characteristics.For patients requiring systemic therapy,immunotherapy combined with chemotherapy has reshaped the first-line treatment landscape,with the most definite benefits observed in the dMMR/MSI-H population,while the optimal treatment pathway for the pMMR population remains to be further optimized.Patients with HER2-positive highly aggressive subtypes and those with ER/PR-positive,relatively slow-progressing disease can also benefit from corresponding targeted or endocrine therapies.At the same time,radiotherapy and other local treatments still have significant value in patients with local recurrence,pelvic-limited recurrence,and oligometastases.This article based on recent evidence,reviews,pre-treatment evaluation,systemic drug therapy,and local treatment strategies for advanced and recurrent endometrial cancer,aiming to provide a reference for standardized management.关键词
子宫内膜癌/晚期/复发/分子分型/免疫治疗/放疗Key words
endometrial cancer/advanced/recurrent/molecular classification/immunotherapy/radiotherapy分类
医药卫生引用本文复制引用
林劲楷,向阳..晚期及复发性子宫内膜癌规范化辅助治疗[J].中国实用妇科与产科杂志,2026,42(5):515-520,6.基金项目
首都卫生发展科研专项(2022-1-4011) Capital Health Development Research Special Project(2022-1-4011) （2022-1-4011）
